Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

NCT06918782 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

DRUG: Osimertinib plus platinum doublet chemotherapy

Sponsor

The University of Hong Kong